6:25 PM
 | 
May 09, 2016
 |  BC Extra  |  Company News

Medicines Co. selling some CV assets to Chiesi

The Medicines Co. (NASDAQ:MDCO) is selling its non-core cardiovascular assets to Chiesi Farmaceutici S.p.A. (Parma, Italy). The deal includes Cleviprex clevidipine, Kengreal cangrelor and the company's rights to ready to use argatroban. It does not include anticoagulant Angiomax bivalirudin, Medicines Co.'s best selling drug, which has faced generic competition in the U.S. since July 2015 and is the subject of ongoing patent litigation with the...

Read the full 349 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >